An interventional study of Liquid Embolic System (Tonbridge) and Onyx Liquid Embolic System (Medtronic) in Intracranial Arteriovenous Malformations, sponsored by Zhuhai Tonbridge Medical Tech. Co., Ltd.. Recruiting at 14 sites in China. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2024-09-19.
Sponsored by Zhuhai Tonbridge Medical Tech. Co., Ltd. · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 13 studies in Intracranial Arteriovenous Malformations with a site in China — 4 open to participants now, 4 under way, none of them phase 3. Intracranial Arteriovenous Malformations · China.
Among the 13 studies in Intracranial Arteriovenous Malformations with a site in China, this one is the only one that started in 2024, is one of 4 with no phase, and was the 10th registered.
43 studies on the registry are indexed under Intracranial Arteriovenous Malformations; 15 are open to participants now.
Browse Intracranial Arteriovenous Malformations studies →4 of the 13 studies in Intracranial Arteriovenous Malformations with a site in China are open now. Recruiting first, the newest first:
Duan Chuanzhi · Sites in China
Beijing Tiantan Hospital · Sites in China
Ages 18–70
Beijing Tiantan Hospital · Sites in China
Ages 18+
A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →
Of the 13 Intracranial Arteriovenous Malformations studies recruiting now, 10 (77%) set no upper age limit and 2 (15%) stop at 75 or younger; 6 take children under 18; 1 takes healthy volunteers.
This study: 18 Years to 80 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
13 studies; the count open now beside each. This study's row is marked.
First in 2012; this study’s year is marked. 1 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 170 is above the median of 85 across 18 interventional studies indexed under Intracranial Arteriovenous Malformations.
Median enrollment 460 across the 6 interventional studies, 300 across the 7 observational. Of the 2 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
3 of 13 have an industry lead sponsor. The 8 most frequent:
Zhuhai Tonbridge Medical Tech. Co., Ltd. is the lead sponsor of 5 studies on the registry; 2 are open to participants now.
Zhuhai Tonbridge Medical Tech. Co., Ltd. has 1 study filed under Intracranial Arteriovenous Malformations — fewer than ten, so there is no comparison to draw.
1 of the studies in Intracranial Arteriovenous Malformations with a site in China that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07118631Beijing Tiantan HospitalClinical Study on Emergency Treatment of Cerebral Arteriovenous Malformation Bleeding | 2027-11-30 |
Add it to your calendar (.ics) → With an account.
Among the 13 studies in Intracranial Arteriovenous Malformations with a site in China, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to verify the efficacy and safety of the Liquid Embolic System (Tonbridge Medical Tech. Co., Ltd. (Suzhou)) for the treatment of cerebrovascular malformations.
This is a prospective, multi-center, randomized, parallel positive controlled, non-inferiority trial. This clinical trial is conducted at more than 2 centers in China, and patients who intend to be treated with liquid embolic system for cerebrovascular malformations are enrolled. Eligible patients are randomized into experimental group using Liquid Embolic System (Tonbridge) or control group using Onyx Liquid Embolic System (Medtronic) in a 1:1 ratio. The purpose of this study is to evaluate the effectiveness and safety of the Liquid Embolic System (Tonbridge).
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.
Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
INR, PT and aPTT (clotting tests)
Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.
Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Device: Liquid Embolic System (Tonbridge)
Device: Onyx Liquid Embolic System (Medtronic)
Endovascular treatment with Liquid Embolic System (Tonbridge).
Endovascular treatment with Onyx Liquid Embolic System (Medtronic).
Targeted Embolization Satisfaction Rate
Targeted embolization satisfaction is defined as achieving ≥50% occlusion of the targeted embolized area after treatment with liquid embolic system, which is determined by immediate postoperative cerebrovascular DSA.
Time frame: intra-procedure
mRS score
mRS scores are assessed at each evaluation time point.
Time frame: 1 month±7 days, 3 months±30 days, 6 months±30 days, 12 months±45 days post-procedure
GOS score
GOS scores are assessed at each evaluation time point.
Time frame: 1 month±7 days, 3 months±30 days, 6 months±30 days, 12 months±45 days post-procedure
Operation satisfaction rate
The 5-point Likert scale is used to evaluate operation satisfaction from three aspects: visualization, diffusion, and microcatheter withdrawal. "Operation satisfaction rate" is defined as the proportion of investigational devices or comparators with Likert score≥12 points.
Time frame: intra-procedure
Incidence of major adverse events (MAEs)
MAEs are defined as intracranial hemorrhage and ischemic complications. Intracranial hemorrhage included intraoperative hemorrhage (puncture of blood-supplying arteries by catheters or guidewires, rupture of nidus, and injury to blood vessels during withdrawal of catheters) and delayed symptomatic hemorrhage in the postoperative period; and ischemic complications included intraoperative ischemic complications (displacement of liquid embolic agents, thrombosis, and so on) and postoperative symptomatic ischemic stroke. "Incidence of major adverse events" is the proportion of subjects with adverse events using the investigational device or the comparator.
Time frame: 1 month±7 days, 3 months±30 days post-procedure
Incidence of adverse events (AEs)
"Incidence of adverse events" is the proportion of subjects with adverse events using the investigational device or the comparator.
Time frame: 1 month±7 days, 3 months±30 days, 6 months±30 days, 12 months±45 days post-procedure
Incidence of serious adverse events (SAEs)
"Incidence of serious adverse events" is the proportion of subjects with serious adverse events using the investigational device or the comparator.
Time frame: 1 month±7 days, 3 months±30 days, 6 months±30 days, 12 months±45 days post-procedure
Incidence of device deficiency
Device deficiency is the unreasonable risk that may endanger human health and life safety in the normal use of medical devices during clinical trials, such as labeling errors, quality problems and malfunctions.
Time frame: 3 months±30 days, 6 months±30 days, 12 months±45 days post-procedure
Not enrolling at this site.
Plan to share: No
No publications or documents are linked to this record.
Started Jun 2024 (actual). Primary completion is estimated for Oct 2025, 16 months after the start.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Intracranial Arteriovenous Malformations →
Zhuhai Tonbridge Medical Tech. Co., Ltd.